Table 3.
Estimated potential impact of mNGS testing on application of antimicrobial agents in patients with severe community-acquired pneumonia
| Modifications | Antimicrobial agents | N (%) |
|---|---|---|
| De-escalation | 174 (52.9) | |
| Remove 1 agent | 109 (33.1) | |
| MXF | 30 | |
| MEM | 19 | |
| VAN | 12 | |
| TZP | 13 | |
| TMP-SMZ | 14 | |
| CAS | 21 | |
| Reduce spectrum of agent | 65 (19.8) | |
| MXF to LZD | 9 | |
| MXF + TZP to MXF + GCV | 42 | |
| MXF + TZP to MXF + Oseltamivir | 14 | |
| Escalation | 86 (26.1) | |
| Add 1 agent | 69 (20.9) | |
| VAN | 8 | |
| MEM | 10 | |
| DOX | 12 | |
| TMP-SMZ | 6 | |
| FLC | 14 | |
| VOR | 9 | |
| Oseltamivir | 10 | |
| Add 2 agent | 17 (5.2) | |
| TMP-SMZ + CAS | 17 | |
| No change | 69 (21.0) |
CAS caspofungin, DOX doxycycline, FLC fluconazole, LZD linezolid, MEM meropenem, MXF moxifloxacin, TMP-SMZ sulfamethoxazole and trimethoprim, TZP piperacillin-tazobactam, VAN vancomycin, VOR voriconazole